Linvoseltamab for Multiple Myeloma: Results from IMS 2023 With Madhav Dhodapkar, MD

At the International Myeloma Society (IMS) 2023 Annual Meeting and Exposition, Dr. Madhav Dhodapkar, Director of the Cancer Center at Emory University, presented the results of the LINKER-MM1 trial of linvoseltamab for relapsed/refractory multiple myeloma. Here, he further delves into the efficacy of linvoseltamab observed in the trial and its projected place in the treatment landscape.